• 1
    Turner N, Gross R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 1167.
  • 2
    Kimelman D, Kirschner M. Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 1987; 51: 86977.
  • 3
    McWhirter JR, Goulding M, Weiner JA, et al. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 1997; 124: 322132.
  • 4
    Wiedemann M, Trueb B. Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics 2000; 69: 2759.
  • 5
    Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199213.
  • 6
    Vainikka S, Joukov V, Wennström S, et al. Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO 1992; 11: 427380.
  • 7
    Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285: 516470.
  • 8
    Wu A, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 2011; 6: 111.
  • 9
    Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282: 2727784.
  • 10
    Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumour progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012; 12: 56.
  • 11
    Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160: 2295307.
  • 12
    Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 6597.
  • 13
    French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 2012; 7: e36713.
  • 14
    Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000; 275: 154829.
  • 15
    Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 21725.
  • 16
    Knisely AS, Strautnieks SS, Meier Y, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44: 47886.
  • 17
    Walters JRF, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 118994.
  • 18
    Lin TY, Chen KM, Chen YR, Lin WS, Wang TH. Icteric type hepatoma. Med Chir Dig 1975; 4: 26770.
  • 19
    Alves R, Alves D, Guz B, et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011; 10: 217.
  • 20
    Manizate F, Hiotis SP, Labow D, Roayaie S, Schwartz M. Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology 2010; 78(Suppl. 1): 1314.
  • 21
    Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparin sulphate in a binary complex with the receptor kinase. J Biol Chem 1999; 274: 1594752.
  • 22
    Ho KH, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 11827.
  • 23
    Abelev GI, Eraiser TL. Cellular aspects of alpha-fetoprotein reexpression in tumours. Semin Cancer Biol 1999; 9: 95107.
  • 24
    Walters JRF, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010; 3: 34957.
  • 25
    Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24: 205064.
  • 26
    Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G9408.
  • 27
    Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 72935.
  • 28
    Zweers SJLB, Booij KAC, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012; 55: 57583.
  • 29
    Schapp FG, van der Gaag NA, Gouma DJ, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49: 122835.
  • 30
    Jung D, Inagaki T, Gerard RD, et al. FXR agonists and FGF15 reduce faecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res 2007; 48: 2693700.
  • 31
    Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 12535.
  • 32
    Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 2668795.
  • 33
    Ito S, Fujimori T, Furuya A, et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J Clin Invest 2005; 115: 22028.
  • 34
    Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 17417.
  • 35
    Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietry and leptin-deficient diabetes. Endocrinology 2004; 145: 2594603.
  • 36
    Abu-Elheiga L, Wu H, Gu Z, et al. Acetyl-CoA carboxylase 2−/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietry and de novo lipogenic conditions. J Biol Chem 2012; 287: 1257888.
  • 37
    Miyazaki M, Flowers MT, Sampath H, et al. Hepatic stearoyl-Coa desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007; 6: 48496.
  • 38
    Huang X, Yang C, Luo Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 56: 250110.
  • 39
    Wu X, Ge H, Lemon B, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. PNAS 2009; 106: 1437984.
  • 40
    Weinstein M, Xu X, Ohvama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998; 125: 361523.
  • 41
    Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 144553.
  • 42
    Chen JY, Levy-Wilson B, Goodart S, Cooper AD. Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed high fat diet. J Biol Chem 2002; 277: 4258895.
  • 43
    Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 2001; 262: 25765.
  • 44
    Cornelius CE. The use of nonhuman primates in the study of bilirubin metabolism and bile secretion. Am J Primatol 1982; 2: 34354.
  • 45
    Pai R, French D, Ma N, et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomologus monkeys. Toxicol Sci 2012; 126: 44656.
  • 46
    Steiger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2010; 42: 43745.
  • 47
    Jansen PL. Endogenous bile acids as carcinogens. J Hepatol 2007; 47: 4345.
  • 48
    Fukuda M, Kawahara Y, Hirota T, et al. Genetic polymorphisms of hepatic ABC-transporter in patients with hepatocellular carcinoma. J Cancer Ther 2010; 1: 11423.
  • 49
    El-Houseini ME, Amer MA, El-Din AHS, et al. Evaluation of serum total bile acids in the diagnosis of hepatocellular carcinoma. J Egypt Natl Canc Inst 2000; 12: 30713.
  • 50
    Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of hepatocellular carcinoma. Mol Cell Proteomics 2011; doi:10.1074/mcp.M110.004945.
  • 51
    Wang B, Chen D, Chen Y, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012; 11: 121727.
  • 52
    El-Mir MY, Badia MD, Luengo N, et al. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clin Sci 2001; 100: 499508.
  • 53
    Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism an hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590600.
  • 54
    Chen Y, Song X, Valanejad L, et al. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology 2013; 57: 153141.
  • 55
    Minami Y, Kudo M. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig Dis 2012; 30: 5927.
  • 56
    Lau W, Leung K, Leung T, et al. A logical approach to hepatocellular carcinoma presenting with jaundice. Ann Surg 1997; 225: 2815.
  • 57
    Abe T, Kajiyama K, Harimotot N, et al. Intrahepatic bile duct recurrence of hepatocellular carcinoma without detectable liver tumour. Int J Surg Case Rep 2012; 3: 2758.
  • 58
    Liu Q, Chen J, Li H, et al. Hepatocellular carcinoma with bile duct tumor thrombi: correlation of magnetic resonance features to histopathologic manifestations. Eur J Radiol 2010; 76: 1039.
  • 59
    Spahr L, Frossard JL, Felley C, et al. Biliary migration of hepatocellular carcinoma fragment after transcatheter arterial chemoembolization therapy. Eur J Gastroenterol Hepatol 2000; 12: 2434.
  • 60
    Bertolotti M, Zambianchi L, Carulli L, et al. Influence of newly synthesised cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 2003; 38: 93946.